Neurocrine Biosciences Inc Shares Up 7.49 percent on Oct 30

NBIX Stock  USD 140.90  2.19  1.58%   
Slightly above 69 percent of all Neurocrine Biosciences' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Neurocrine Biosciences suggests that a large number of traders are confidant. Neurocrine Biosciences' investing sentiment can be driven by a variety of factors including economic data, Neurocrine Biosciences' earnings reports, geopolitical events, and overall market trends.
  
Shares of Neurocrine Biosciences Inc surged 7.49 percent in mid-day trading on Oct 30. The stock reached an intraday high of 131.26, before settling at 124.

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

Neurocrine Biosciences Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Neurocrine Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Neurocrine Biosciences Maximum Pain Price Across March 21st 2025 Option Contracts

Neurocrine Biosciences' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Neurocrine Biosciences close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Neurocrine Biosciences' options.

Neurocrine Biosciences Fundamental Analysis

We analyze Neurocrine Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Neurocrine Biosciences is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Neurocrine Biosciences Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neurocrine Biosciences stock to make a market-neutral strategy. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics with similar companies.

Peers

Neurocrine Biosciences Related Equities

ITCIIntracellular   14.91   
0%
57.0%
PCRXPacira BioSciences,   11.09   
0%
42.0%
ANIPANI Pharmaceuticals   1.62   
0%
6.0%
EVOEvotec SE   1.16   
0%
4.0%
DVAXDynavax Technologies   0.08   
0%
1.0%
PBHPrestige Brand   0.51   
1.0%
0%
AMPHAmphastar   0.74   
2.0%
0%
ALKSAlkermes Plc   1.20   
4.0%
0%
COLLCollegium Pharmaceutical   1.29   
4.0%
0%
SUPNSupernus Pharmaceuticals   1.50   
5.0%
0%
IRWDIronwood Pharmaceuticals   13.54   
51.0%
0%
AVDLAvadel Pharmaceuticals   26.10   
100.0%
0%

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.